Corcept Therapeutics (CORT) Net Cash Flow (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Net Cash Flow data on file, last reported at -$11.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 69.98% year-over-year to -$11.5 million; the trailing twelve-month figure through Mar 2026 stood at $18.1 million (up 130.17% YoY), and the FY2025 full-year result was -$8.6 million, down 12.46% from the prior year.
• Net Cash Flow slipped to -$11.5 million in Q1 2026, from -$4.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $233.6 million in Q1 2023 to a low of -$127.6 million in Q2 2023.
• A 5-year average of $1.8 million and a median of -$4.6 million in 2025 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow jumped 2107.68% in 2022 and tumbled 506.64% in 2023, its largest moves.
• Tracing CORT's Net Cash Flow over 5 years: stood at $16.1 million in 2022, then soared by 45.42% to $23.4 million in 2023, then tumbled by 137.9% to -$8.9 million in 2024, then soared by 47.99% to -$4.6 million in 2025, then sank by 148.75% to -$11.5 million in 2026.
• Business Quant data shows CORT's Net Cash Flow at -$11.5 million in Q1 2026, -$4.6 million in Q4 2025, and $22.7 million in Q3 2025.